PAC CARDIO-2 Tomo 2
Contenido
REFERENCIAS

  1. Lacy MC. Cardiopatía isquémica en la mujer: Fisiopatología y comportamiento clínico. En: Férez S, ed. Monografía del curso “Cardiopatía Isquémica Crónica”. México, 1996: 83-84.

  2. Aleixo A. Postmenopausal women: what is special? Rev Port Cardiol 1998; 17: 581-584.

  3. Serrano PA. Factores de riesgo coronario. Arch Inst Cardiol Méx 1973; 43:892-902.

  4. Salazar E, Moragrega JL, Magos C, Zorrilla E, Serrano PA. Alteraciones metabólicas en sobrevivientes de infarto del miocardio. Arch Inst Cardiol Méx 1973; 43: 4-17.

  5. Chávez RI. Cardiopatía isquémica por aterosclerosis coronaria. México: Salvat, 1980: 15.

  6. Wenger NK, Speroff L, Packard B. Cardiovascular health and disease in women. N Engl J Med 1993; 329: 247-256.

  7. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA 1995;265:1861-1867.

  8. Rotberg T, Segovia E, Gorodezky M. Reinfarto del miocardio en el sexo masculino y femenino. Arch Inst Cardiol Méx 1978; 48: 631-652.

  9. Lozano Ascencio R, Escamilla Cejudo JA, Escobedo de la Peña J, López Cervantes M. Tendencia de la mortalidad por cardiopatía isquémica en México. Salud Pública de México 1990; 32: 405-415.

  10. Organización Panamericana de la Salud. Condiciones de salud en las Américas. Enfermedades cardiovasculares. 1994. Reproducido en Directivo Médico 1997; IV (2): 13-18.

  11. Férez S, Alexánderson E. Cardiopatía isquémica en la mujer. Arch Inst Cardiol Méx 1991; 61: 193-195.

  12. Camacho Hernández R, Corona I, Vázquez JL, Martínez F, Escobedo J. Factores de riesgo para cardiopatía isquémica en México: un estudio de casos clínicos y testigos. Arch Inst Cardiol Méx 1995;65:315-322.

  13. De Barbieri T. Cambios en la situación de la mujer. Demos. Carta demográfica sobre México. 1997: 32-33.

  14. Chávez Domínguez R. Factores de riesgo coronario en la mujer. En: Férez S, ed. Monografía del curso Cardiopatía Isquémica Crónica. México, 1996. pp. 83-84

  15. Brett KM, Madans JH. Long-term survival after coronary heart disease. Comparisons between men and women in a national sample. Ann Epidemiol1995; 5: 25-32.

  16. Hazzard WR. Why do women live longer than men? Biologic differences that influence longevity. Postgrad Med 1989; 85: 271-278.

  17. Hazzard WR, Applebaum-Bowden D. Why women live longer than men: the biologic mechanism of the sex differential in longevity. Trans Am Clin Climatol Assoc 1989; 101: 168-188.

  18. Mosca L, Manson JE, Sutherland SE, Langer RD, Manolio T, Barret-Connor E. Cardiovascular disease in women. A statement for healthcare professionals from the American Heart Association. Circulation 1997; 96: 2468-2482.

  19. Fiebach NH, Hebert PR, Stampfer MJ, Colditz GA, Willett WC, Rosner B, et al. A prospective study of high BP and cardiovascular disease in women. Am J Epidemiol 1989; 130: 646-654.

  20. Isles C. Blood pressure in males and females. J Hypertens 1995; 13: 285-290.

  21. Marcuschamer J. Fases en la progresión de las cardiopatías hipertensiva y coronaria. En. Arriaga J, Marcuschamer J. Inhibidores de la ECA. Un decenio de experiencia clínica. Interamericana-McGraw-Hill, 1992: 11-27.

  22. Rubio-Guerra AF, Lozano JJ, Vargas G, Rodríguez L, Sánchez AR. Aspectos recientes en la fisiopatología de la hipertensión arterial. Med Int Méx 1997; 13: 294-300.

  23. Vargas G, Rubio-Guerra AF, Lozano JJ, Rodríguez L, Torres A. El óxido nítrico: más que un factor relajante endotelial. Med Int Méx 1996; 12: 110-116.

  24. Contreras Anastasio MD, García Mendoza JJ. Prevalencia de hipertensión arterial sistémica en Tehuacán, Puebla. En: Sánchez Torres G, ed. Hipertensión arterial sistémica. De su impacto poblacional a las vicisitudes terapéuticas. México: Sociedad Mexicana de Cardiología, 1993:11-12.

  25. Méndez Vargas R, Ayala Barajas C, Blanco Muñoz J, Lozano Ascencio R, Escamilla Cejudo JA. Panorama de la hipertensión arterial y sus factores de riesgo en la República Mexicana. En: Sánchez Torres G, ed. Epidemiología de las enfermedades cardiovasculares en México. México: Sociedad Mexicana de Cardiología, 1992: 37-53.

  26. Chávez Rivera I. Hipertensión arterial esencial. México: Edit. Croissier, S. A., 1985: 69-92.

  27. Kaplan NM. Clinical hypertension. 7ª ed. Baltimore: Williams and Wilkins, 1998: 118.

  28. Beshansky J, Selker H. Hospital mortality in women and men with acute cardiac ischemia: a prospective multicenter study. JACC 1997; 29: 1490-1496.

  29. Whelton PK, Hej, Appel LS. Treatment and prevention of hypertension. En: Manson JE, Ridker PM, Gåziano JM, Hennekens CH, ed. Prevention of Myocardial infarction. New York: Oxford University Press, 1996:154-171.

  30. Saltzberg S, Stroh JA, Frishman WH. Isolated systolic hypertension in the elderly: pathophysiology and treatment. Med Clin North Am 1988;72: 523-547.

  31. Kaplan NM. Clinical hypertension. 7ª ed. Baltimore: Williams and Wilkins, 1998: 3.

  32. Kannel WB. Blood pressure as a cardiovascular risk factor. JAMA 1996; 275: 1571-1576.

  33. Vokonas PS, Kannel WB, Cupples LA. Epidemiology and risk of hypertension in the elderly: the Framingham Study. J Hypertens 1988; 6 (Suppl. 1): S3-S9.

  34. Ascherio A, Hennekens C, Willet WC et al. Prospective study of nutritional factors, blood pressure, and hypertension among US women. Hypertension 1996; 27: 1065-1072

  35. Solís-Morales H, Alvarado-Ruíz R, Núñez-Fragoso JC, Rodríguez-Morán M, Guerrero-Romero JF. Perfil de riesgo cardiovascular en pacientes con hipertensión arterial sistémica de la ciudad de Durango. Med Int Méx 1998; 14: 8-12.

  36. Garber AM, Browner WS, Hulley SB. Cholesterol screening in asymptomatic adults, revisited. Ann Intern Med 1996; 124 (5): 518-531.

  37. Isles CG, Hole DJ, Hawthorne VM, Lever AF. Relation between coronary risk and coronary mortality in women of the Renfrew and Presley Survey: comparison with men. Lancet 1992; 339: 702-706.

  38. Jacobs D, Blackburn H, Higgins M, Reed D, Iso H, McMillan G, et al. Report of the conference on low blood cholesterol: mortality associations. Circulation 1992; 86: 1046-1060.

  39. Hulley SB, Walsh JM, Newman T. Health policy on blood cholesterol. time to change directions (Editorial). Circulation 1992; 86: 1026-1029.

  40. Ochoa Sosa CA, Posadas Romero C. Dislipoproteinemias en México. En: Sánchez Torres G, ed. Epidemiología de las enfermedades cardiovasculares en México. México: Sociedad Mexicana de Cardiología, 1992: 17-28.

  41. Matthews KA, Meilahn E, Keller LH, Kelsey SF, Caggiula AW, Wing RR. Menopause and risk factors from coronary heart disease. N Engl J Med 1989; 321: 641-646.

  42. Jacobs DR, Meban IL, Bangdiwala SI, Criqui MH, Tyroler HA. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipids Research Clinics Prevalence Study. Am J Epidemiol 1990; 131: 32-47.

  43. Sevilla Moya JC, de Febrer Martínez G, Jammoul A, Masana Marín L. Lípidos como factor de riesgo en mujeres. Rev Lat Cardiol 1998; 19: 63-67.

  44. Isles CG, Hole DJ, Lever AF, Hawthorne VM. Risk factors from coronary disease and stroke in men and women. Quartely J Med 1996; 89: 343-349.

  45. Waters D, Higginson L, Gladstone P, Boccuzzi SJ, Cook Th, Lespérance J, et al. Effects of cholesterol lowering on the progression of coronary atherosclerosis in women: a Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) substudy. Circulation 1995; 92: 2404-2410.

  46. American College of Physicians. Guidelines for using serum cholesterol, high-density lipoprotein cholesterol, and triglyceride levels as screening tests for preventing coronary heart disease in adults. Ann Intern Med 1996; 124: 515-517.

  47. Masana Marín L. Dislipidemias. Evidencias para su tratamiento. Rev Lat Cardiol 1998; 19: 33-34.

  48. LaRosa JC. Triglycerides and coronary risk in women and the elderly. Arch Intern Med 1997; 157: 961-968.

  49. Brunzell JH, Austin M. Plasma triglyceride levels and coronary disease. N Engl J Med 1989; 320:1273-1274.

  50. Lewis B, Assmann G, Tikkanen M, Mancini M, Pometta, Stein Y, et al. Prevention of coronary heart disease. Scientific background and new clinical guidelines. Recommendations of the European Atherosclerosis society prepared by the International Task Force for the prevention of coronary heart disease. En: Assmann G, ed. Lipid metabolism disorders and coronary heart disease. 2ª ed. Munich: MMV Medizin Verlag, 1993: 98.

  51. Haffner SM, González C, Miettine H, Howard BV, Stern MP. LDL size and subclass pattern in Mexico City residents and San Antonio Mexican Americans. Arterioscler Thromb Vasc Biol 1995; 15: 2136-2141.

  52. Jammoul A, Sardà Auré P, Masana Marín L. Estudio y control analítico evolutivo de las hiperlipidemias. Rev Lat Cardiol 1998; 19: 41-46.

  53. Lawn RM. Lipoprotein (a) in heart disease. Scientific American 1992; 266(6):54-60.

  54. Angles-Cano E, Hervio L, Loyau. Lipoprotéine (a), hypofibrinolyse et athérothrombose, quo vadis? Sang Thrombose Vaisseaux 1995; 7: 315-322.

  55. Rainwater DL. Genetic basis for multimodal relationship between apolipoprotein (a) size and lipoprotein (a) concentration in Mexican-Americans. Atherosclerosis 1995; 115: 165-171.

  56. Utermann G. The mysteries of lipoprotein (a). Science1989; 246: 904-910.

  57. Averna MR, Barbagallo CM, Ocello S, Doria O, Davi G, Scafidi V, et al. Lp(a) levels in patients undergoing aorto-coronary bypass surgery. Eur Heart J 1992; 13: 1405-1409.

  58. Stiel GM, Reblin T, Bührlen M, Latterman A, Nienaber ChA. Differences in lipoprotein (a) and apolipoprotein (a) levels in men and women with advanced coronary atherosclerosis. Coronary Artery Disease 1995; 6: 347-350.

  59. Bostom AG, Gagnon DR, Cupples A, Wilson PWF, Jenner JL, Ordovas JM, Schaefer EJ, Castelli WP. A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women. The Framingham Heart Study. Circulation 1994; 90: 1688-1695.

  60. Ochoa SCA, Zamora GJ, González HJA, Ize LI, Cardoso SG, Posadas RC. Lipoproteína(a) en hipercolesterolemia familiar heterocigota. Arch Inst Cardiol Méx 1994; 64:549-555.

  61. Olvera S, Posadas C, Izaguirre R, Quiroz A, Pastelín G. Estrógenos, aterosclerosis y trombosis. Nueva Cardiología 1996; 6: 393-405.

  62. Tapia-Conyer R, Cravioto P, de la Rosa Montaño B. Tabaquismo en México, implicaciones preventivas. En: Sánchez Torres G, ed. Epidemiología de las enfermedades cardiovasculares en México. México: Sociedad Mexicana de Cardiología, 1992:29-36.

  63. Willett WC, Green A, Stampfer MJ, Speizer FE, Colditz GA, Rosner B, et al. Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes. N Engl J Med 1987; 317: 1303-1309.

  64. Verschuren WMM, Kromhout D. Total cholesterol concentration and mortality at relatively young age: do men and women differ? BMJ 1995; 311: 779-783.

  65. Lewis B, Assmann G, Tikkanen M, Mancini M, Pometta, Stein Y, et al. Prevention of coronary heart disease. Scientific background and new clinical guidelines. Recommendations of the European Atherosclerosis society prepared by the International Task Force for the prevention of coronary heart disease. En: Assmann G, ed. Lipid metabolism disorders and coronary heart disease. 2ª ed. Munich: MMV Medizin Verlag, 1993: 80-81.

  66. Palmer JR, Rosenberg L, Shapiro S. “Low yield” cigarrettes and the risk of nonfatal myocardial infaction in women. N Engl J Med 1989;320:1569-1573.

  67. Rosenberg L, Palmer JR, Shapiro S. Decline in the risk of myocardial infarction among women who stop smoking. N Engl J Med 1990; 322:213-217.

  68. Colditz GA, Bonita R, Stampfer MJ, Willet WC, Rosner B, Speizer FE, Hennekens CH. Cigarrette smoking and risk of stroke in middle-aged women. N Engl J Med 1988;318:937-941.

  69. Stover DE. Women, smoking, and lung cancer. Chest 1998; 113: 1-2.

  70. Pierce JP, Fiore MC, Novotny TE, Hatziandreu EJ, Davis RM. Trends in cigarette smoking in the United States: projections to the year 2000. JAMA 1989; 261: 61-65.

  71. Rivera Benítez C, Jaramillo Olea M, Valdés Lías E. Síndrome de enfermedad metabólica. Med Int Méx 1996; 12: 172-180.

  72. Lewis B, Assmann G, Tikkanen M, Mancini M, Pometta, Stein Y, et al. Prevention of coronary heart disease. Scientific background and new clinical guidelines. Recommendations of the European Atherosclerosis society prepared by the International Task Force for the prevention of coronary heart disease. En: Assmann G, ed. Lipid metabolism disorders and coronary heart disease. 2ª ed. Munich: MMV Medizin Verlag, 1993: 74.

  73. Zavaroni Y, Bonora E, Pagliara M, et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med 1989; 320: 702-705 .

  74. Walton C, Godsland IF, Proudler AJ, Wynn V, Stevenson JC. The effects of the menopause on insuline sensivity, secretion and elimination on non-obese, healthy women. Eur J Clin Invest 1993; 23: 466-473.

  75. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham Study. JAMA 1979; 241: 2035-2038.

  76. Barrett-Connor E, Wingard DL. Sex differential in ischemic heart disease mortality in diabetics: a prospective population study. Am J Epidemiol 1983; 118: 489-496.

  77. Lundberg V, Stegmayr B, Asplund K, Eliasson M, Huhtasaari F. Diabetes as a risk factor for myocardial infarction: population and gender perspectives. J Intern Med 1997; 241: 485-492.

  78. García MJ, McNamara PM, Gordon T, Kanner WB. Sixteen year follow-up study. Morbidity and mortality in diabetics in the Framingham population. Diabetes 1976;23:105.

  79. Lerman GI, Ramírez JC, García E, Luna K, Posadas C. La diabetes mellitus no-dependiente de insulina incrementa la mortalidad temprana por infarto agudo del miocardio. Arch Inst Cardiol Méx 1993;63:317-323.

  80. Lloyd CE, Kuller LH, Ellis D, Becker DJ, Wing RR, Orchard TJ. Coronary artery disease in IDDM. Gender differences in risk factors but not risk. Arterioscler Thromb Vasc Biol 1996; 16: 720-726.

  81. Lewis B, Assmann G, Tikkanen M, Mancini M, Pometta, Stein Y, et al. Prevention of coronary heart disease. Scientific background and new clinical guidelines. Recommendations of the European Atherosclerosis society prepared by the International Task Force for the prevention of coronary heart disease. En: Assmann G, ed. Lipid metabolism disorders and coronary heart disease. 2ª ed. Munich: MMV Medizin Verlag, 1993: 81.

  82. Ramiro Hernández M, Curiel Hernández O. Diabetes mellitus. Complicaciones cardiovasculares. Actualidades en Medicina Interna 1998; 9:50.

  83. Wren BG. The menopause. En: Hacker NF, MooreJG, ed. Essentials of obstetrics and gynecology. 2ª ed. Philadelphia: W.B. Saunders Co, 1992: 543-550.

  84. Khaw KT. Epidemiology of the menopause. Br Med Bull 1992; 48: 249-261.

  85. Tunstall-Pedoe H. Myth and paradox of coronary risk and the menopause. Lancet 1998; 351: 1425-1427.

  86. Kittler ME. Differences in men and women in coronary artery disease, systemic hypertension and their treatment. Am J Cardiol 1992; 70: 1077-1080.

  87. González C, Stern M. La obesidad como factor de riesgo cardiovascular en México. Estudio en población abierta. Rev Invest Clin 1993; 45:13-21.

  88. Manson JE, Stampfer MJ, Colditz GA, Willett WC, Rosner B, Monson RR, et al. A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med 1990; 322: 882-889.

  89. Castro G, Godínez Gutiérrez SA. Obesidad. Actualidades en Medicina Interna 1998; 1: 2-20.

  90. Huang Z, Willett WC, Manson JE, Rosner B, Stampfer MJ, Speixer FE, Colditz GA. Body weigth, weight change, and risk for hypertension in women. Ann Intern Med 1998; 128: 81-88.

  91. Bijnen FCH, Caspersen CJ, Mosterd WL. Physical inactivity as a risk factor for coronary heart disease: a WHO and International Society and Federation of Cardiology position statement. Bulletin of the World Health Organization 1994; 72: 1-4.

  92. Manson JE, Lee I-M. Exercise for women: how much pain for optimal gain? N Engl J Med 1996; 334: 1325-1327.

  93. Scarabin PY, Vissac AM,Kirsin JM, Bourgeat P, Amiral J, Agher R, Guize L. Population correlates of coagulation factor VII. Importance of age, sex and menopausal status as determinants of activated factor VII. Arterioscler Thromb Vasc Biol 1996;16: 1170-1176.

  94. Gebara OCE, Mittleman MA, Sutherland P, et al. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation 1995;91:1952-1958

  95. Meade TW, Cooper JA, Chakrabarti R, Miller GJ, Stirling Y, Howarth DJ. Fibrinolytic activity and clotting factors in ischaemic heart disease in women. BMJ 1996;312;1581

  96. Held C, Hjemdahl P, Rehnqvist N, Allen NH, Forslund L, Björkander I, Angelin B, Wiman B. Haemostatic markers, inflammatory parameters and lipids in male and female patients in the Angina Prognosis Study in Stockholm (APSIS). A comparison with healthy controls. J Intern Med 1997; 241: 59-69.

  97. Robinson K, Arheart K, Refsum H, Brattström L, Boers F, Ueland P, et al. Low circulating folate and vitamin B6 concentrations: risk factors for stroke, peripheral vascular disease, and coronary artery disease. European COMAC Group. Circulation 1998; 97(5):437-443.

  98. Nygård O, Norderhaug J, Refsum H, Veland P, Farstad M, Vollset S. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230-236.

  99. Folsom AR, Nieto FJ, McGovern PG, Tsai MY, Malinow MR, Eckfeldt JH, Hess DL, Davis CE. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins. The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1998; 98: 204-210.

  100. Graham IM, Daly LE, Refsum H, Robinson K, Brattström LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997;277:1775-1781.

  101. Birdsall MA, Farquhar CM, White HD. Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Ann Intern Med 1997; 126:32-35.

  102. Stampfer MJ, Willet WC, Colditz GA, Speizer FE, Hennekens CH. A prospective study of past use of oral contraceptive agents and risk of cardiovascular disease. N Engl J Med 1988;319:1313-1317.

  103. Spitzer WO. Balance view of risks of oral contraceptives. Lancet 1997; 350:1566-1567.

  104. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the genders: a 26-year follow-up of the Framingham population. Am Heart J 1986; 111: 383-390.

  105. Willich SN, Lowel H, Lewis M, et al. Unexplained gender differences in clinical symptoms of acute myocardial infarction. J Am Coll Cardiol 1993; 21: 238A.

  106. Rotberg T, Segovia E, Gorodezky M. Reinfarto del miocardio en el sexo masculino y femenino. Arch Inst Cardiol Méx 1978; 48: 631-652.

  107. Mulcahy D, Dakak N, Zalos G, Andrews NP, Proschan M, Waclawiw MA, et al. Patterns and behavior of transient myocardial ischemia in stable coronary disease are the same in both men and women: A comparative study. JACC 1996; 27: 1629 - 1636.

  108. Diamond GA, Forrester JS. Analysis of probability as an aid in the clinical diagnosis of coronary artery disease. N Engl J Med 1979; 300: 1350-1358.

  109. Khan SS, Nessim S, Gray R, Czer LS, Chaux A, Matloff J. Increased mortality of women in coronary artery bypass surgery: evidence of referral bias. Ann Intern Med 1990; 112: 561-567.

  110. Férez S, Shapiro M. Adaptación cardiovascular a la prueba de esfuerzo. México: Salvat, 1980: 163-193.

  111. Sketch MH, Mohiuddin SM, Lynch JD, Zencka AE, Runco V. Significant sex differences in the correlation of electrocardiographic exercise testing and coronary arteriograms. Am J Cardiol 1975; 36: 169-173.

  112. Masini M, Picano E, Lattanzi F, Distante A, L’Abbate A. High-dose dipyridamole-echocardiography test in women: correlation with exercise-electrocardiography test and coronary angiography. J Am Coll Cardiol 1988; 12: 682-685.

  113. Blomstrand P, Engvall J, Swahn E, Säfström K, Thulesius O, Wranne B. Cardiovascular effects of dobutamine stress testing in women with suspected coronary artery disease. Heart 1996; 75: 463-468.

  114. Caballero R, Solorio S, Badui E, Almazán A, Madrid R, Rangel A, Lepe L, Ayala F, Murillo H. Prueba de estrés farmacológico eco-dobutamina en cardiopatía isquémica. Arch Inst Cardiol Méx 1994; 64: 355-360.

  115. Guadalajara Boo JF, Galván O, Marrufo R, Cervantes JL, Huerta D. Diagnóstico de la isquemia miocárdica mediante ecocardiograma dinámico digitalizado con dobutamina y atropina. Arch Inst Cardiol Méx 1995; 65: 330-341.

  116. Boley JJ, Heinle SK, Kisllo J. Dobutamine stress echocardiography: influence of gender on test accuracy. J Am Coll Cardiol 1996; 27 (Suppl.): 404A.

  117. Ho Y-L, Wu Ch-Ch, Huang P-J, Lin L-Ch, Chieng P-U, Chen W-J, et al. Assessment of coronary artery disease in women by dobutamine stress echocardiography: comparison with stress thallium-201 single-photon emission computed tomography and exercise electrocardiography. Am Heart J 1998; 135: 655-662.

  118. Sawada SG, Ryan T, Fineberg NS, Armstrong WF, Judson WE, McHenry PL, et al. Exercise echocardiographic detection of coronary artery disease in women. J Am Coll Cardiol 1989; 14: 1440-1447.

  119. DePuey EG, Garcia EV. Optimal specificity of thallium-201 SPECT through recognition of imaging artifacts. J Nucl Med 1989; 30: 441-449.

  120. Hansen CL, Crabbe D, Rubin S. Lower diagnostic accuracy of thallium-201 SPECT myocardial perfusion imaging in women: an effect of smaller chamber size. J Am Coll Cardiol 1996; 28: 1214-1219.

  121. Amanullah AM, Kiat H, Friedman JD, Berman DS. Adenosine technetium-99m sestamibi myocardial perfusion SPECT in women: diagnostic efficacy in detection of coronary artery disease. J Am Coll Cardiol 1996; 27: 803-809.

  122. Hachamovitch R, Berman DS, Kiat H, Bairey Merz CN, Cohen I, Cabico A, et al. Effective risk stratification using exercise myocardial perfusion SPECT in women: gender-related differences in prognostic nuclear testing. J Am Coll Cardiol 1996; 28: 34-44.

  123. Iskandrian AE, Heo J, Nallamothu N. Detection of coronary artery disease in women with use of stress single-photon emission computed tomography myocardial perfusion imaging. J Nucl Cardiol 1997; 4: 329-335.

  124. Geleijnse ML, Elhendy A, von Domburg RT, Cornel JH, Reijs AEM, Fioretti PM. Prognostic significance of normal dobutamine-atropine stress testing sestamibi scintigraphy in women with chest pain. Am J Cardiol 1996; 77: 1057-1061.

  125. Travin MI, Duca MD, Kline GM, Herman SD, Demus DD, Heller GV. Relation of gender to physician use of test results and to the prognostic value of stress technetium 99m sestamibi myocardial single-photon emission computed tomography scintigraphy. Am Heart J 1997; 134: 73-82.

  126. He ZX, Dakik HA, Vaduganathan P, Qureshi U, Mahmarian JJ, Verani MS. Clinical and angiographic significance of a normal thallium-201 tomographic study in patients with a strongly positive exercise electrocardiogram. Am J Cardiol 1996;78:638-641.

  127. Shaw LJ, Miller Dd, Romeis JC, Kargl D, Younis LT, Chaitman BR. Gender differences in the noninvasive evaluation and management of patients with suspected coronary artery disease. Ann Intern Med 1994; 120: 559-566.

  128. Mark DB; Shaw LK, DeLong ER, Califf RM, Pryor DB. Absence of gender bias in the referral of patients for cardiac catheterization. N Engl J Med 1994; 330: 1101-1106.

  129. Dodge JT Jr, Brown BG, Bolson EL, Dodge HT. Lumen diameter of normal coronary arteries. Influence of age, sex, anatomic variation, and left ventricular hypertrophy or dilation. Circulation 1992; 86: 232-296.

  130. Tweddel AC, Martin W, Hutton I. Thallium scans in syndrome X. Br Heart J 1992;68(1):48-50.

  131. Zajarías A. Síndrome X cardiológico. En: Fernández de la Reguera G, ed. Cardiopatía isquémica 2: Temas de Medicina Interna 1996; 4: 563-567.

  132. Likoff W, Segal BL, Kasparina H. Arteriograms in patients considered to have unmistakable coronary heart disease. N Engl J Med 1967; 276: 1063.

  133. Waxler EB, Kimbris D, Dreifus LS. The fate of women with normal coronary arteriograms and chest pain resembling angina pectoris. Am J Cardiol 1971; 28: 26.

  134. Coma Canella MI, Alfonso Pulpón L, Fernández de Miguel JM, González González M, Artaza Andrade M, Martín Judez V. Correlación entre manifestaciones clínicas, el electrocardiograma y las coronarias en un grupo de pacientes con angor. Arch Inst Cardiol Méx 1977; 47: 83-94.

  135. Kaski JC, Rosano GMC, Collins P, Nihoyannopoulos P, Maseri A, Poole-Wilson PA. Cardiac syndrome X: clinical characteristics and left ventricular function. J Am Coll Cardiol 1995; 25: 807-814.
135a. Rosano GM, Peters NS, Lefroy D, Lindsay DC, Sarrel PM, Collins P, Poole-Wilson PA. 17-beta-Estradiol therapy lessens angina in postmeno-pausal women with syndrome X. J Am Coll Cardiol 1996;28(6):1500-1505.
  1. Roth A, Elkayam U. Acute myocardial infarction associated with pregnancy. Ann Intern Med 1996; 125: 751-762.

  2. Vélez M, Alcocer R, Peláez JC, Jauregui R, Alvarez H, Narvaéz J. Infarto agudo del miocardio en el puerperio. Reporte de un caso y revisión de la literatura. Arch Inst Cardiol Méx 1994; 64: 361-366.

  3. Cohen WR, Steinman T, Patsner B, Snyder D, Satwicz P, Monroy P. Acute myocardial infarction in a pregnant woman at term. JAMA 1983; 250: 2179-2181.

  4. Demirovic J, Myerburg RJ. Epidemiology of sudden coronary death: an overview. Prog Cardiovasc Dis 1994; 37: 39-48.

  5. Myerburg RJ, Kessler KM, Castellanos A. Pathophysiology of sudden cardiac death. PACE 1991;14:935-944.

  6. Burke AP, Farb A, Malcom GT, Liang Y, Smialek J, Virmani R. Effect of risk factors on the mechanism of acute thrombosis and sudden coronary death in women. Circulation 1998; 97(21):2110-2116.

  7. Oparil S. Pathophysiology of sudden coronary death in women. Implications for prevention. Circulation 1998; 97(21):2103-2105.

  8. Antiplatelet Trialists’ Collaborative. Collaborative overview of randomized trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81.

  9. Fiol Sala M, Viñolas Prat X. Tratamiento farmacológico en la prevención secundaria postinfarto de miocardio (III): bloqueadores betaadrenérgicos. Rev Lat Cardiol 1995; 16: 230-239.

  10. Acute Infarction Ramipril efficacy (AIRE). Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-828.

  11. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 334: 1383-1389.

  12. Fiol Sala M, Guindo Soldevilla J. Tratamiento farmacológico en la prevención secundaria postinfarto de miocardio (I): impacto del tratamiento fibrinolítico. Rev Lat Cardiol 1995; 16: 138-151.

  13. Weaver WD, et al. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. JAMA 1996; 10: 777-782.

  14. Arrieta Sandoval LL. Comparación de la trombolisis en el infarto agudo del miocardio entre pacientes del sexo masculino y femenino. Tesis de Postgrado. Facultad de Medicina. UNAM. México 1998.

  15. Weitzman S, Cooper L, Chambless L, Rosamond W, Clegg L, Marcucci G, et al. Gender, racial, and geographic differences in the performance of cardiac diagnostic and therapeutic procedures for hospitalized acute myocardial infarction in four states. Am J Cardiol 1997; 79: 722-726.

  16. Wolfe MW, Roubin GS, Schweiger M, Isner JM, Fergusson JJ, Cannon AD, et al. Length of hospital stay and complications after percutaneous transluminal coronary angioplasty. Clinical and procedural predictors. Circulation 1995; 92: 311-319.

  17. Herlitz J, Bang A, Hartford M, Karlson BW. Influence of gender on survival, mode of death, reinfarction, use of medication, and aspects of well being during a period of five years after the onset of acute myocardial infarction. Clin Cardiol 1996; 19: 555-561.

  18. Chaitman BR, Fisher LD, Bourassa MG, Davis K, Rogers WJ, Maynard Ch, et al. Effect of coronary bypass surgery on survival patterns in subsets of patients with left main coronary artery disease. Report of the Collaborativa Study in Coronary Artery Surgery (CASS). Am J Cardiol 1981; 48: 765-777.

  19. Buffolo E, Silva de Andrade JC, Rodriguez Branco JN, Teles CA, Figuereido Aguiar L, Gomes WJ. Coronary artery bypass grafting without cardiopulmonary bypass. Ann Thorac Surg 1996; 61: 63-66.

  20. Canto de Cetina TE. Terapia de sustitución hormonal en el climaterio. Rev Invest Clin 1995; 47: 49-61.

  21. Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK, et al. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. N Engl J Med 1993; 328: 1069-1075.

  22. Collins P, Rosano GMC, Jiang C, Lindsay D, Sarrel PM, Poole-Wilson PA. Cardiovascular protection by oestrogen. A calcium antagonist effect? Lancet 1993;341:1264-1265.

  23. Du XJ, Riemersma RA, Dart AM. Cardiovascular protection by oestrogen in partly mediated through modulation of autonomic nervous function. Cardiovasc Res 1995; 30:161-165.

  24. Hazzard WR. Estrogen replacement and cardiovascular disease: serum lipids and blood presure effects. Am J Obstet Gynecol 1989; 161: 1847-1853.

  25. Psaty BM, Heckbert SR, Atkins D, Lemaitre R, Koepsell TD, Wahl PW, et al. The risk of myocardial infarction associated with the combined use of estrogen and progestin in postmenopausal women. Arch Intern Med 1994; 154: 1333-1339.

  26. O´Keefe JH, Kim SC, Hall RR, Cochran VC, Lawhorn SL, McCallister BD. Estrogen replacement therapy after coronary angioplasty in women . J Am Coll Cardiol 1997; 29: 1-5.

  27. Sidney S, Petitti DB, Quesenberry CP Jr. Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women. Ann Intern Med 1997; 127: 501-508.

  28. Walsh BW, Schiff Y, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991; 325: 1196-1204.

  29. Sacks FM, McPherson R, Walsh BW. Effect of postmenopausal estrogen replacement on plasma Lp (a) lipoprotein concentrations. Arch Intern Med 1994; 154: 1106-1110.

  30. Chetkowsky RJ, Meldrum DR, Steingold KA, Rankle D. Biological effects of transdermal estradiol. N Engl J Med 1986; 314: 1615-1620.

  31. Ottosson UB, Johansson BG, von Schoultz B. Subfractions of high-density lipoprotein cholesterol during estrogen replacement therapy: A comparison between progestogens and natural progesterone. Am J Obstet Gynecol 1985; 151: 746-750.

  32. Medical Research Council´s General Practice Framework. Randomised comparison of oestrogen versus oestrogen plus progestogen hormone replacement therapy in women with histerectomy. BMJ 1996; 312: 473-478.

  33. The writing group for the PEPI trial. Effects of estrogen or estrogen-progestine regimens on heart disease risk factors in postmenopausal women. JAMA 1995; 273:199-213.

  34. Grodstein F, Stampfer MJ, Colditz GA, Willet WC, Manson JE, Joffe M, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336: 1769-1775.

  35. Siddle NC, Jessinger DK, Whitehead MI, Turner P, Lewis B, Prescott P. Effects on plasma lipids and lipo-proteins of postmenopausal oestrogen therapy with added dihydrogestreone. Brit J Obstet Gynaecol 1990; 97: 1093-1100.

  36. Kim YD, Chen B, Beauregard J, Kouretas P, Thomas G, Farhat MY, et al. 17 beta-estradiol prevents dysfunction of canine coronary endothelium and myocardium and reperfusion arrithmias after brief ischemia/reperfusion. Circulation 1996; 94: 2901-2908.

  37. Darling GM, Johns JA, McCloud PI, Davis SR. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. N Engl J Med 1997; 337: 595-601.

  38. Lip GY, Beevers M, Churchill D, Beevers DG. Hormone replacement therapy and bood pressure in hypertensive women. J Human Hypertens 1994; 8: 491-494.
173a. Lip GY, Beevers M, Churchill D, Beevers DG. Hormone replacement therapy and blood pressure in hypertensive women. J Hum Hypertens 1994;8(7):491-494.
  1. Modena MG, Rossi R, Muia NJr, Origliani G, Rombola O, Molinari R. Short-term results of transdermal estrogen replacement therapy in cardiovascular disease-free postmenopausal females with and without hypertension. G Ital Cardiol 1998; 28: 636-644.

  2. Koh KK, Mincemoyer R, Rui MN, Csako G, Pucino F, Guetta V, et al. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 1997; 336: 683-690.

  3. Williams JK, Adams MR, Klopfenstein HS. Estrogen modulated responses of atheroesclerotic coronary arteries. Circulation 1990; 81: 1680-1687.

  4. Furchgott RF. The 1996 Albert Lasker Medical Research Awards. The discovery of endothelium-derived relaxing factor and its importance in the identification of nitric oxide. JAMA 1996; 276: 1186-1188

  5. Moncada S. Nitric oxide. J Hypertens 1994; 10: S35-S39.

  6. Hayashi T, Fukuto JM, Ignarro LJ, Chaudhuri G. Basal release of nitric oxide from aortic rings is greater in female rabbits than in male rabbits: implications for atherosclerosis. Proc Natl Acad Sci USA 1992; 89: 11259-11263.

  7. Sánchez A, Gómez MH, Dorantes AL, Rosales JL, Pastelín G, Díaz V, et al. The effect of ovarectomy on depressed contractions to phenylephrine and KCl and increase relaxation to acetylcholine in isolated aortic rings of female compared to male rabbits. Br J Pharmacol 1996; 118: 2017-2022.

  8. Gaxiola E, Olvera Cruz S, Salazar E. A propósito de la cardiopatía isquémica en la mujer: papel de los estrógenos en la pared vascular coronaria y en el síndrome X. Arch Inst Cardiol Méx 1995; 65: 461-467.

  9. Lieberman EH, Gerhard MD, Uehata A, Walsh BW, Selwyn AP, Ganz P, et al. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med 1994; 121: 936-941.

  10. Collins P, Rosano GM, Sarrel PM, Ulrich L, Adamopoulos S, Beale CM, et al. 17 beta-estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation 1995; 92: 24-30.

  11. Venkov CD, Rankin AB, Vaughan DE. Identification of authentic estrogen receptor in cultured endothelial cells. A potential mechanism for steroid hormone regulation of endothelial function. Circulation 1996; 94(4):727-733.

  12. Lobo RA, Pickar JH, Wild RA, Walsh B, Hirvonen E. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. The Menopause Study Group. Obstet Gynecol 1994; 84(6):987-995.

  13. Lindheim SR, Legro RS, Bernstein L, et al. Behavioral stress responses in premenopausal and postmenopausal women and the effects of estrogen. Am J Obstet Gynecol 1992; 167: 1831-1836.

  14. Ryne SM, Goldberger AL, Pincus SM, Mietus J, Lipsitz LA. Gender- and age-related differences in heart rate dynamics: are women more complex than men? J Am Coll Cardiol 1994; 24: 1700-1707.

  15. Du XJ, Riemersma RA, Dart AM. Cardiovascular protection by oestrogen is partly mediated through modulation of autonomic nervous function. Cardiovasc Res 1995; 30: 161-165.

  16. Kannel WB, Schatzkin A. Sudden death: lessons from subsets in population studies. J Am Coll Cardiol 1985; 5: 141B-149B.

  17. Webb CM, Rosano GMC, Collins P. Oestrogen improves exercise-induced myocardial ischemia in women. Lancet 1998; 351: 1556-1557.

  18. Rosano GMC, et al. Acute anti-ischemic effect of estradiol-17 beta in postmenopausal women with coronary heart disease. Circulation 1997; 96: 2837-2841.

  19. New G, Timmins KL, Duffy SJ, Tran BT, O’Brien RC, Harper RW, Meredith IT. Long-term estrogen therapy improves vascular function in male to female transsexuals. J Am Coll Cardiol 1997; 29: 1437-1444.

  20. McCrohon JA, Walters WA, Robinson JT, et al. Arterial reactivity is enhanced in genetic males taking high dose estrogens. J Am Coll Cardiol 1997; 29: 1432-1436.

  21. Yeung AC. Estrogen for men: reversal of cardiovascular misfortune? J Am Coll Cardiol 1997; 29: 1445-1446.

  22. Férez Santander SM, De la Peña Almaguer E, Márquez MF, Eid Lidt G. Daño miocárdico por reperfusión: su impacto en la clínica. Arch Inst Cardiol Méx 1998; 68: 431-437.

  23. Kim YD, Chen B, Beauregard J, Kouretas P, Thomas G, Farhat MY; Myers AK, Lees DE. 17 beta-estradiol prevents dysfunction of canine coronary endothelium and myocardium and reperfusion arrhythmias after brief ischemia/reperfusion. Circulation 1996; 94: 2901-2908.

  24. Persson I, Adami HO, Bergkvist L, et al. Risk of endometrial cancer after treatment with estrogens alone or in conjunction with progestogens: results of a prospective study. BMJ 1989; 298: 147.

  25. Steinberg KK, Thacker SB,Smith Sj, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991; 265: 195.

  26. Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 1989; 321: 293-297.

  27. Barrett-Connor E. Postmenopausal estrogen replacement and breast cancer. N Engl J Med 1989; 321: 319-320.

  28. Grodstein F, Colditz GA, Stampfer MJ. Postmenopausal hormone use and cholecystectomy in a large prospective study. Obstet Gynecol 1994; 83:5.

  29. Collins LC, Peiris A. Bronchospasm secondary to replacement estrogen therapy. Chest 1993; 104: 1300.

  30. Troisi RJ, Speizer FE, Willet WC, et al. Menopause, postmenopausal estrogen preparations, and the risk of adult-onset asthma. Am J Respir Crit Care Med 1995; 152: 1183.

  31. Felson DT, Zhang Y, Hannan MT, Kiel DP, Wilson PWF, Anderson JJ. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993; 329: 1141-1146.

  32. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E for the Heart and estrogen Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-613.

  33. Petitti DB. Hormone replacement therapy and heart disease prevention. Experimentation trumps observation. JAMA 1998; 280: 650-652.

  34. The Women’s Health Initiative Study Group. Design of the Women’s Health Initiative clinical trial and observational study. Control Clin Trials 1998; 19: 61-109.

  35. Fuleihan GEH. Tissue-specific estrogens-the promise for the future. N Engl J Med 1997; 337: 1686-1687.

  36. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux A-C, Shah AS, Huster WJ, Draper M, Christiansen C. Effect of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337: 1641-1647.

  37. Gustafsson JA. Raloxifene: magic bullet for heart and bone. Nature 1998; 4: 152-153.

  38. Hu FB, Stampfer MJ, Manson JE, Rimm E, Coldtiz GA, Rosner BA, Hennekens CH, Willet WC. Dietary fat intake and the risk of coronary heart disease in women. N Engl J Med 1997; 337: 1491-1499.

  39. Mensink RP, Katan MB. Effect of a diet enriched with monounsaturated or polyunsatured fatty acids on levels of low-density and high-density lipoprotein cholesterol in healthy women and men. N Engl J Med 1989; 321:436-441.

  40. Hernández López GD, Lozano Nuevo JJ, Rodríguez López L, Torres Viloria A, Vargas Ayala G, Rubio Guerra F. Modificaciones en el perfil de lípidos inducidas al agregar nueces a la dieta del paciente hipercolesterolémico. Med Int Méx 1997; 13: 214-217.

  41. Gordon T, Kannel WB. Drinking habits and cardiovascular disease: The Framingham Study. Am Heart J 1963; 105: 667-673.

  42. Castelli WP. How many drinks a day? J Am Med Assoc 1979; 242: 2000.

  43. Castelli WP, Hjortland MC, Kaga A, Doyle JT, Hames CG, Hulley SB, Zukel WJ. Alcohol and blood lipids. Lancet 1977; 2: 153-155.

  44. Hendricks HF, Veenstra J, Veithuis-te Wierick EJM, Schaafsma G, Kluft C. Effect of moderate dose of alcohol with evening meal on fibrinolytic factors. Br Med J 1994; 308: 1003-1006.

  45. Gorinstein S, Zemser M, Lichman I, Berebi A, Kleipfish A, Libman I, Trakhtenberg S, Caspi A. Moderate beer consumption and the blood coagulation in patients with coronary artery disease. J Intern Med 1997; 241: 47-51.

  46. Hertog MGL, Feskens EJM, Hollman PCH, Katan MB, Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: The Zutphen Elderly Study. Lancet 1993; 342: 1007-1011.

  47. Constant J. Alcohol, ischemic heart disease, and the French Paradox. Clin Cardiol 1997; 20: 420-424.

  48. Bradley KA, Boyd-Wickizer J, Powell SH, Burman ML. Alcohol screening questionnaires in women. A critical review. JAMA 1998; 280: 166-171.

  49. Hammar N, Romelsjo A, Alfredson L. Alcohol consumption, drinking pattern and acute myocardial infarction. A case referent study based on the Swedish Twin Register. J Intern Med 1997; 241: 125-131.

  50. Gaziano JM, Buring JE, Breslow JL, Goldhaber SZ, Rosner B, Vanderburgh M, Willett W, Henneken CH. Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction. N Engl J Med 1993; 329: 1829-1834.

  51. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study. Lancet 1996; 347: 781-786.
224a. Kushi LH, Folsom AR, Prineas RJ, Mink PJ, Wu Y, Bostick RM. Dietary antioxidant vitamins and death from coronary heart disease in post-menopausal women. N Engl J Med 1996;334(18):1156-1162.
  1. Rapola JM, Virtamo J, Ripatti S, Huttunen JK, Albanes D, Taylor PR, Heinonen OP. Randomised trial of alpha-tocopherol and beta carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet 1997; 349: 1715-1720.

  2. Virtamo J, Rapola JM, Ripatti S, Heinonen OP, Taylor PR, Albanes D, Huttunen JK. Effect of vitamin E and beta-carotene on the incidence of primary nonfatal myocardial infarction and fatal coronary heart disease. Arch Intern Med 1998; 23: 668-675.

  3. Buring JE, Hennekens CH, for the WHSRG. The Women’s Health Study: summary of the study design. J Myocardial Ischemia 1992; 4: 27-29.

  4. Williams PT. High-density lipoprotein cholesterol and other risk factors for coronary heart disease in female runners. N Engl J Med 1996; 334:1298-1303

  5. Vázquez Cabrer G. El programa de rehabilitación cardíaca del Instituto Nacional de Cardiología de México. Nueva Cardiología 1996; 6: 386-391.



Contenido
Copyright © 2005 Dr. Scope. Derechos Reservados.
Diseño y Programación: Educación Médica Contínua